posit challeng segment
color segment medic segment clear focu today call given
weak segment outperform expect period
manag attribut weak roll patient recoveri tsa
agreement suppli chain integr issu legaci medic busi
specif within america tsa roll apac unfortun integr
busi creat backlog fill rate result weak quarter
compani work address issu seem issu may remedi
quickli silver line demand seemingli remain solid busi
segment may bounc back integr issu settl asid
integr issu also saw higher cost relat commod
advers impact busi cordi busi in-lin expect
pharmaceut side busi specialti busi
perform well help drive upsid segment common theme across
drug distributor directli comment gener deflat
compani indic trend consist seemingli worsen
posit custom contract management note anyth
ordinari relat just-ink renew price reset consist custom
size new price expect take effect juli cah final
relat opioid-rel expens management indic expenditur gener
track in-lin mln expect thu far
lower ep expect maintain ep estim
despit magnitud beat lower expect improv
medic busi also trim ep
medic segment profit factor higher opioid relat expens
previous under-model shift valuat basi maintain ew
rate pt base price-to-earnings ep
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
equal weight equal weight
compani continu go transit relat
medic busi core drug
distribut busin continu lap headwind
upsid case see gener price improv
brand inflat come slightli exoecatuib
lead multipl expans
downsid case see gener price continu
remain heavili deflationari slower expect
improv seen cordi busi lead
lower price multipl contract
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
singl digit growthlow singl digit growthmid singl digit growthmid singl digit growthnon-gaap effect tax expens milnon-gaap dilut milcapit milpharma segmentrevenu growthlow singl digit growthlow singl digit growthmid high singl digit growthmid high singl digit growthprofit ebit growthhigh singl low doubl digit declinehigh singl low doubl digit declinehigh singl low doubl digit declinehigh singl low doubl digit declinegener pricingsimilar pricingmid-singl digitmid-singl digitmid-singl digitmid-singl digitmed segmentrev growthlow singl digit growthlow singl digit growthapproxim flatapproxim flatebit growthmid high singl digit growthmid high singl digit growthmid high singl digit growthlow mid singl digit declin barclay cardin
 quarterli revenu model mil cahcahcahcahcahcahcahrevenu revenuepharmaceut distribut elimin growthpharmaceut distribut elimin total revspharmaceut distribut elimin quarterli oper profit mil cahcahcahcahcahcahcahoper profit ebit ebit ebit ebit barclay
 quarterli incom statement distribut sell addback oper addback check excl intang asset ens rate minor check ep fulli dilut share growth distribut sell per barclay
 annual revenu model mil cahcahcahrevenu revenuepharmaceut distribut elimin growthpharmaceut distribut elimin total revspharmaceut distribut elimin annual oper profit mil cahcahcahoper profit ebit ebit ebit ebit barclay
 annual incom statement distribut sell addback oper addback check excl intang asset ens rate minor check ep fulli dilut share growth distribut sell per barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
